Nymox files proposals with US FDA for AlzheimAlert
This article was originally published in Clinica
Executive Summary
Supporting its second attempt to gain US approval for a test kit version of its urine test for Alzheimer's disease, Nymox has filed with the FDA further proposals regarding its premarket approval (PMA) application for the product.